Patient and Provider Demand for and Readiness to Adopt Medications for Stimulant Use Disorders in Real-World
Enya B Vroom1,2,3, Erin P Finley1,2,3,4,5, Carma Deem Bolton2,4
1Center for Research to Advance Community Health, Long School of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Introduction:
In the United States, rates of stimulant use disorder (StUD) have increased over the last 20 years, yet fewer than one-third of adults receive treatment. Recent research has shown the efficacy of medication for StUD, but little is known regarding demand and readiness to adopt such treatments. This study examined patient and provider perspectives on medication for StUD in real-world practice settings.
Methods:
Semi-structured interviews were conducted with patients with substance use disorder (SUD) history (n = 20) and SUD care team members (n = 20) currently providing SUD services. Interviews elicited perceptions of treatment demand, barriers/facilitators, and recommendations for future implementation. Rapid qualitative analysis was used to distill and compare findings across groups. Analysis was guided by the Health Equity Implementation Framework (HEIF), selected for its focus on implementation and social determinants.
Results:
Consistent with HEIF, multilevel patient and care team barriers and facilitators were identified, reflecting the importance of the clinical encounter and highlighting implementation challenges within the inner, outer and societal contexts, particularly related to stigma. Training for providers and education for patients and families were recommended to overcome stigma. Utilising patient-centred care approaches and addressing societal factors impacting treatment engagement were also discussed as likely to affect medication access.
Discussion And Conclusions:
Examining patient and care teams' perceptions of medications for StUD improves understanding of demand and readiness for adoption. This information, rooted in lived experiences, provides a foundation for selecting tailored implementation strategies that may assist in accelerating the adoption of medications to treat StUD in future scale-up and spread.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
Related Concept Videos
Drug Therapy
Antianxiety Medications
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Psychosis: Goals of Pharmacotherapy
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
